KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Operating Margin: 2019-2025

Historic Operating Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -11.41%.

  • Esperion Therapeutics' Operating Margin rose 1963.00% to -11.41% in Q3 2025 from the same period last year, while for Sep 2025 it was -9.67%, marking a year-over-year decrease of 1524.00%. This contributed to the annual value of 16.37% for FY2024, which is 15009.00% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Operating Margin stood at -11.41%, which was down 232.45% from 8.61% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Operating Margin registered a high of 52.47% during Q1 2024, and its lowest value of -1,038.15% during Q1 2021.
  • For the 3-year period, Esperion Therapeutics' Operating Margin averaged around -52.20%, with its median value being -31.04% (2024).
  • In the last 5 years, Esperion Therapeutics' Operating Margin spiked by 300,782bps in 2021 and then tumbled by 19,798bps in 2022.
  • Over the past 5 years, Esperion Therapeutics' Operating Margin (Quarterly) stood at -361.20% in 2021, then surged by 13,528bps to -225.92% in 2022, then surged by 9,455bps to -131.37% in 2023, then skyrocketed by 12,498bps to -6.40% in 2024, then surged by 1,963bps to -11.41% in 2025.
  • Its Operating Margin stands at -11.41% for Q3 2025, versus 8.61% for Q2 2025 and -34.00% for Q1 2025.